NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Publication of Final Terms in relation to the issue of €750,000,000 fixed rate euro medium term notes AstraZeneca PLC has published the following Final Terms: Final Terms dated 20 November 2014 (the "Final Terms") relating to the issue by AstraZeneca PLC of €750,000,000 fixed rate euro medium term notes maturing on 24 November 2021 with a coupon of 0.875 per cent. (the "Notes") pursuant to its U.S.$5,000,000,000 Euro Medium Term Note Programme (the "EMTN Programme"). The Final Terms must be read in conjunction with the base prospectus for the EMTN Programme dated 24 June 2014 (the "Base Prospectus") and supplementary prospectus for the EMTN Programme dated 17 November 2014 (the "Supplementary Prospectus"). The proceeds of the issue of the Notes will be used to fund the repayment of outstanding euro medium term notes in an aggregate principal amount of €750,000,000 maturing in January 2015. To view the Final Terms for the above mentioned issue, please paste the following URL into the address bar of your browser: http://www.rns-pdf.londonstockexchange.com/rn...-11-24.pdf A copy of the Final Terms for the above mentioned issue will shortly be submitted to the National Storage Mechanism and will be available for inspection at: http://www.morningstar.co.uk/uk/NSM Disclaimer - intended addressees Please note that the information contained in the Final Terms (when read together with the information in the Base Prospectus and Supplementary Prospectus) may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Final Terms, Base Prospectus and Supplementary Prospectus is not addressed. Prior to relying on the information contained in the Final Terms, the Base Prospectus and the Supplementary Prospectus you must ascertain whether or not you are part of the intended addressees of the information contained therein. In particular, the Final Terms, the Base Prospectus and the Supplementary Prospectus in respect of the Notes do not constitute an offer of securities for sale in the United States. The Notes have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended, (the "Securities Act") or under any relevant securities laws of any state of the United States of America and may not be offered or sold to, or for the account or benefit of U.S. persons or persons within the United States of America, as such terms are defined in Regulation S under the Securities Act, except in certain transactions exempt from, or not subject to, the registration requirements of the Securities Act. There will be no public offering of the securities in the United States. Your right to access the Final Terms is conditional upon complying with the above requirement. A C N Kemp Company Secretary 24 November 2014
Publication of Final Terms NOT FOR RELEASE, PUBLICATION OR
Top 10 Most Recent News Articles
Rare Stellar Merger Validates RIT Theory in Nature
One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...
Continue Reading
America's Group Adds Swansea to Its UK Auction Map
A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...
Continue Reading
Berlin Heals Puts Microcurrent Therapy to a Real Test
A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....
Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze
Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...
Continue Reading
JOYY’s Ad Engine Gives Q3 Growth Some Real Teeth Now
Three engines are finally pulling the cart at JOYY, and that is a far more interesting sight than another quarter of livestreaming merely holding together. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% sequentially. Those are sturdy numbers, especially for a business that investors have long tended to box in as...
Continue Reading
Replit Bets on Trusted Creators to Sell AI Agents at Work
Forty-five creators may sound like a marketing footnote, but Replit is aiming at a real enterprise bottleneck: people do not buy grand AI slogans; they buy proof that a messy internal problem can actually get fixed. Its newly launched Replit & Co. program puts business and technology creators in front of that problem, with product access, demonstrations and direct contact...
Continue Reading
Term or Whole Life: Costs, Coverage, and Trade-Offs
A life insurance choice can sit quietly in a drawer for years, then become brutally important at exactly the wrong moment. Laura Wood's November 18, 2026 comparison of term and whole life insurance is useful for that reason: it keeps dragging the conversation back to the unglamorous stuff that actually matters—how long coverage lasts, what it costs, and whether a...
Continue Reading
OCEG Faces China's Demographic Test After 40 Years
A school group that once opened 35 kindergartens in a year is admitting the old playbook has run its course. That is the real message behind Oriental Cambridge Education Group's 40th-anniversary talk, not the balloons and ceremonial language. OCEG operates more than 170 institutions across 39 Chinese cities, and its chairman, Yu Yue, says the next chapter will be judged...
Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod
A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....
Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings
American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....
Continue ReadingTop 5 Most Recently Viewed Articles
Proaction Secures $4.2M to Challenge Legacy Fleet Firms
Fleet Management: A Market Ripe for Disruption You ever cruised past an old clunker of a business model and thought, "Now there's a setup ripe for a rethink"? That's exactly what Proaction's up to with their recent $4.2 million cash injection. For anyone keeping tabs on the legacy fleet management scene, it’s like watching someone take a claw hammer to a creaky old...
Continue Reading
Mission Bio Unveils Groundbreaking Solution for Genome Analysis
Mission Bio dropped the bomb back in 2024 with its Tapestri Genome Integrity CNV Solution, a serious piece of kit aimed at transforming how researchers tackle genomic integrity. This ain't just another offering; it’s the first single-cell high-throughput solution that measures genome-wide copy number variations (CNVs). Think of it as a lifeline for those deep in...
Continue Reading
Varonis Shines as a Leader in Data Security Platforms
Varonis Receives Prestigious Recognition in Data Security Varonis Systems, Inc. (Nasdaq: VRNS) is excited to receive acknowledgment as a Leader within the data security landscape, as highlighted by a prominent research firm in their latest report. This recognition emphasizes Varonis’ commitment to securing data effectively while continuously evolving their platform to...
Continue Reading
CocoFest 2025: Embracing Community and Wellness Together
CocoFest 2025: A Celebration of Community and Wellness CocoFest is returning for its third rendition, bringing together people for a day dedicated to celebrating love and wellness. This exciting event will take place on a Saturday at the Boca Raton Innovation Campus, showcasing how love can enhance our lives in various ways. What to Expect at CocoFest 2025 The festival...
Continue Reading
Innovative Speech Therapy Game Enhances Learning for Kids
Innovative Speech Therapy Game Revolutionizes Learning In a vibrant city, an inventive mind has crafted a special game designed to make speech therapy more engaging for children. This game, known as LINGUA TOKENS, aims to bring excitement into learning fundamental speech skills. With a focus on fun, children aged 4 to 9 can enhance their articulation through play-based...
Continue Reading